Clinical Trial: Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Efficient Treatments for ACE-I and ARB-induced Angioedema Exist and Should be Available to All Patients. Analysis of Their Availability and Influencing Factors in the Area
Brief Summary: Specific treatments for angiotensin-converting-enzyme inhibitor (ACE-I) and angiotensin-receptor-blocker (ARB)-induced angioedema exist. Early access to these treatments is challenging because they are expensive and have short shelf lives making it illusory that all emergency department (ED) stock them. The aim of this retrospective study was to define, for each patient with a confirmed ACE-I or ARB-induced angioedema, at which step of the care, the specific treatment was administered. The second objective was to analyse the availability of these treatment in the area around Lyon, France and the factors that may influence it.
Detailed Summary:
Sponsor: Hospices Civils de Lyon
Current Primary Outcome: Step of the care allowing the patients to benefit from a specific treatment. [ Time Frame: October 2010 to December 2014 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Epidemiological characteristics [ Time Frame: October 2010 to December 2014 ]The investigators collect data such as age, sex, localization of the angioedema.
- Triggering treatments [ Time Frame: October 2010 to December 2014 ]The investigators detail which ACE-inhibitor, which ARB and eventually which co-medication was taken and triggered the angioedema.
Original Secondary Outcome: Same as current
Information By: Hospices Civils de Lyon
Dates:
Date Received: July 5, 2016
Date Started: February 2016
Date Completion:
Last Updated: July 7, 2016
Last Verified: July 2016